BriaCell spins off sCD80 cancer therapy to BriaPro in strategic deal

Bavarian Nordic bags $22.5M Canadian vaccine order

The order will cover the manufacturing of bulk vaccine in 2026

Asahi Kasei Pharma & Alchemedicine launch first human trials for hard-to-treat diseases drugs

Apotex scores exclusive Canadian rights to testosterone therapy Nebido

Under the agreement, Apotex’s branded division, Searchlight Pharma, will seek regulatory approval and handle marketing and distribution in Canada

Fitch upgrades Biocon Biologics outlook to positive, affirms ‘BB-’ rating

China nod to Darolutamide for metastatic hormone-sensitive prostate cancer

The approval follows the pivotal Phase III ARANOTE trial, which demonstrated that darolutamide plus ADT cut the risk of radiological progression or death by 46% compared to placebo plus ADT

Biocon Biologics gets credit boost from S&P, outlook stable

The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’

Will Forte joins Teva Pharmaceuticals to shine spotlight on Huntington’s disease

HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life

FDA nod to Boehringer Ingelheim's heart disease treatment for dogs 'Vetmedin'

VETMEDIN (pimobendan) chewable tablets and VETMEDIN solution (pimobendan oral solution) can delay the onset of congestive heart failure (CHF) in dogs

EMA hits record high in vet medicine nods for second year running

EMA recommended 30 veterinary medicines for marketing authorisation in 2025